Ga-68 PSMA PET shows high specificity in predicting lymph node invasion in prostate cancerJuly 12th 2021
With supporting data from larger series, using Ga-68 PSMA PET as a lymph node invasion prediction tool instead of nomograms could avoid unnecessary lymphadenectomies during radical prostatectomy,” said Yakup Kordan, MD.
Next-generation imaging marks dawn of new era in prostate cancer paradigmMarch 16th 2021
At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, highlighted the potential of next-generation imaging to revolutionize the management of patients with prostate cancer.
18F-DCFPyL may aid in staging men with metastatic, nonmetastatic relapsed prostate cancerFebruary 12th 2021
The novel PSMA-targeted radiopharmaceutical for PET identified M1 disease in the majority of patients examined who otherwise had locoregional disease, according to a subanalysis of the OSPREY trial.